Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1-Reference-Cited by-同舟云学术

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

Published:2022-06-15 Issue:12 Volume:132 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Aykul Senem^ORCID,Huang Lily,Wang Lili,Das Nanditha M.,Reisman Sandra^ORCID,Ray Yonaton,Zhang Qian,Rothman Nyanza,Nannuru Kalyan C.,Kamat Vishal^ORCID,Brydges Susannah,Troncone Luca^ORCID,Johnsen Laura,Yu Paul B.^ORCID,Fazio Sergio,Lees-Shepard John^ORCID,Schutz Kevin^ORCID,Murphy Andrew J.^ORCID,Economides Aris N.^ORCID,Idone Vincent^ORCID,Hatsell Sarah J.^ORCID

Funder

Regeneron Pharmaceuticals

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/153792/files/pdf

Reference36 articles.

1. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes

2. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva

3. Novel Mutations in ACVR1 Result in Atypical Features in Two Fibrodysplasia Ossificans Progressiva Patients